Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Yolaine Parlier"'
Autor:
Pauline Brice, Michel Peuchmaur, Nicole Brousse, Felix Reyes, Philippe Solal-Celigny, Michel Leporrier, Eric Lepage, Yolaine Parlier, Christian Gisselbrecht, Corinne Haioun, Bertrand Coiffier, André Bosly
Publikováno v:
New England Journal of Medicine. 329:1608-1614
Background. Interferon alfa and cytotoxic drugs have synergistic effects in patients with non-Hodgkin's lymphoma. In 1986, we designed a clinical trial to evaluate the benefit of concomitant administration of recombinant interferon alfa with a regime
Autor:
Zong Qi Wen, Nicole Dastugue, Yolaine Parlier, Christine Charrin, Gerald Marit, Antoine Broustet, Philippe Bernard, Marie Françoise Berteas, Josy Reiffers, Jacques Pris, Denis Fiere, Jérôme Jaubert, Jacqueline Reynaud
Publikováno v:
European journal of cancer (Oxford, England : 1990). 27
In order to compare the effects of interferon versus hydroxyurea for the treatment of chronic myelogenous leukaemia (CML), 58 CML patients, having received no previous treatment, were randomized into two treatment groups (hydroxyurea or interferon) f
Autor:
Jean Philippe Laporte, Christophe Louvet, Nicole Smadja, Yvan Drolet, Marcel Krulik, Daniel Donadio, Albert Najman, Jean-Marie Del ge, P. Brissaud, Aimery de Gramont, Claude Jacquillat, Jacques Debray, Yolaine Parlier, Ernest Rioux, Michel Boiron
Publikováno v:
Cancer. 59:301-304
Mean corpuscular volume (MCV) evolution during cytotoxic therapy was studied in 32 patients with Hodgkin's disease (HD) who developed therapy-related acute nonlymphocytic leukemia (t-ANLL) and in 64 HD controls matched for age, therapy duration, and
Autor:
Albert Najman, Jean-Philippe Laporte, Yvan Drolet, Mark E. Smith, Michel Boiron, Jean‐Marie Delǎge, Claude Jacquillat, Jacques Debray, Daniel Donadio, Yolaine Parlier, Ernest Rioux, P. Brissaud, Marcel Krulik, Nicole Smadja, Aimery de Gramont, Christophe Louvet
Publikováno v:
Cancer. 58:630-634
Peripheral blood changes preceding therapy-related leukemia were studied in 105 patients who had received cytotoxic therapy, 53 for Hodgkin's disease and 52 for other cancers. Preleukemic anomalies were observed in 74.3% of the cases, appearing after
Publikováno v:
Cancer. 50:401-409
Between January 1973 and January 1979, 131 patients with malignant non-Hodgkin's lymphomas (107 lymphocytic lymphomas, 24 histiocytic lymphomas) were treated with cyclophosphamide-vincristin-prednisone (CVP) either alone or combined with Adriamycin (